Gensight Biologics: Oddo still a buyer, despite delays
(CercleFinance.com) - Oddo maintains its Outperform rating on GenSight Biologics, along with its target price of E7 (cp: E2.
5, -20%).
The announcement of successive delays in the release of Luvemoq should weigh on the stock in the short term, the analyst says, and fuel a feeling of weariness amongst investors.
However, Oddo does not believe that this should call into question the intrinsic qualities of the company, of Lumevoq and its commercial potential.
For the analyst, the company offers an attractive risk/reward profile given the maturity of its pipeline and a discounted valuation.
The main downside to our investment thesis is the dilution associated with the next rounds of financing expected in the short and medium term, Oddo says.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
5, -20%).
The announcement of successive delays in the release of Luvemoq should weigh on the stock in the short term, the analyst says, and fuel a feeling of weariness amongst investors.
However, Oddo does not believe that this should call into question the intrinsic qualities of the company, of Lumevoq and its commercial potential.
For the analyst, the company offers an attractive risk/reward profile given the maturity of its pipeline and a discounted valuation.
The main downside to our investment thesis is the dilution associated with the next rounds of financing expected in the short and medium term, Oddo says.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.